Optimal [(18)F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

Conclusion: In the PHERGain trial, an increased SUVmax cutoff (≥77%) after 2 cycles of exclusive HP (with or without endocrine therapy) achieves a pCR in the range of the control arm with chemotherapy plus HP (59.5% vs. 57.7%, respectively), further identifying a subgroup of patients with HER2-addicted tumors. However, the original cutoff (≥40%) maximizes the number of patients who could avoid chemotherapy.PMID:38575192 | DOI:10.2967/jnumed.123.266384

Source: Cancer Control - April 4, 2024 Category: Cancer & Oncology Authors: Geraldine Gebhart Marleen Keyaerts Thomas Guiot Patrick Flamen Manuel Ruiz-Borrego Agostina Stradella Bego ña Bermejo Santiago Escriva-de-Romani Lourdes Calvo Mart ínez Nuria Ribelles Mar ía Fernandez-Abad Cinta Albacar Marco Colleoni Laia Garrigos Man Source Type: research